Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Sacituzumab Govitecan vs standard chemotherapy in previously treated ES-SCLC
CTR20251057Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in small cell lung cancer (SCLC), sponsored by Gilead Sciences. Started Jul 2025; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20251057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251057.